CFGS
BEAM icon

Concourse Financial Group Securities’s Beam Therapeutics BEAM Stock Holding History

Concourse Financial Group Securities’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$10K – 2403
2021
Q2 		$13K Hold
100
– – ﹤0.01% 1776
2021
Q1 		$8K Hold
100
– – ﹤0.01% 1813
2020
Q4 		$8K Hold
100
– – ﹤0.01% 1744
2020
Q3 		$2K Buy
+100
New +$2.48K ﹤0.01% 1982

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Concourse Financial Group Securities's BEAM Position: Q3 2021 in Review

Concourse Financial Group Securities sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 100 shares — an estimated $10K sold.

Concourse Financial Group Securities first reported a position in BEAM in Q3 2020 and held it in 4 quarters. The position peaked at $13K in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • Concourse Financial Group Securities reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Concourse Financial Group Securities sold 100 Beam Therapeutics shares in Q3 2021, an estimated $10K.
  • Concourse Financial Group Securities first reported a position in Beam Therapeutics in Q3 2020 and held it in 4 quarters.
  • Concourse Financial Group Securities's Beam Therapeutics position peaked at $13K in Q2 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on Concourse Financial Group Securities's 13F filing for Q3 2021, filed 9 Nov 2021.